ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

NRBO NeuroBo Pharmaceuticals Inc

3.73
0.05 (1.36%)
02 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
NeuroBo Pharmaceuticals Inc NRBO NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.05 1.36% 3.73 18:50:01
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
3.67 3.55 3.73 3.73 3.68
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
30/4/202407:01PRNUSNeuroBo to Present Latest Pre-Clinical Data on..
17/4/202407:05PRNUSNeuroBo Pharmaceuticals Doses First Patient in Its Phase 1..
01/4/202407:01PRNUSNeuroBo Pharmaceuticals Completes Enrollment of Part 1 of..
28/3/202407:01PRNUSNeuroBo Pharmaceuticals Reports Year End 2023 Financial..
13/3/202407:01PRNUSNeuroBo Pharmaceuticals Receives Safety Review Committee..
04/3/202407:01PRNUSNeuroBo Pharmaceuticals Appoints Seasoned Life Science..
04/3/202406:30EDGAR2Form 8-K - Current report
29/2/202407:30EDGAR2Form 8-K - Current report
29/2/202407:01PRNUSNeuroBo Pharmaceuticals Receives First Site IRB Approval for..
14/2/202407:52EDGAR2Form 8-K - Current report
12/2/202407:01PRNUSNeuroBo Pharmaceuticals to Participate in the BIO CEO &..
01/2/202407:30EDGAR2Form 8-K - Current report
01/2/202407:01PRNUSNeuroBo Pharmaceuticals Announces FDA Clearance of IND for a..
18/1/202407:30EDGAR2Form 8-K - Current report
18/1/202407:01PRNUSNeuroBo Pharmaceuticals Reports Positive Pre-Clinical Safety..
09/1/202407:45EDGAR2Form 8-K - Current report
09/1/202407:30PRNUSNeuroBo Pharmaceuticals Regains Compliance with Nasdaq..
02/1/202407:01PRNUSNeuroBo to Participate in Industry and Investor Conferences..
28/12/202308:00EDGAR2Form 8-K - Current report
28/12/202307:45PRNUSNeuroBo Pharmaceuticals Submits IND Application to the FDA..
19/12/202308:03EDGAR2Form 8-K - Current report
19/12/202307:43PRNUSNeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock..
07/12/202308:20EDGAR2Form 8-K - Current report
01/12/202307:31PRNUSNeuroBo to Participate in Investor Conferences in December
13/11/202315:29EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202315:14EDGAR2Form 8-K - Current report
13/11/202315:05PRNUSNeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial..
06/11/202307:20EDGAR2Form 8-K - Current report
06/11/202307:05PRNUSNeuroBo Pharmaceuticals Strengthens Board of Directors with..
30/10/202307:06EDGAR2Form 8-K - Current report
17/10/202307:01PRNUSNeuroBo to Present at the H.C. Wainwright 7th Annual NASH..
22/9/202307:03EDGAR2Form 8-K - Current report
19/9/202315:15EDGAR2Form 8-K - Current report
15/9/202307:11EDGAR2Form 8-K - Current report
15/9/202307:01PRNUSNeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a..
24/8/202315:15EDGAR2Form 8-K - Current report
14/8/202315:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/8/202307:18EDGAR2Form 8-K - Current report
14/8/202307:01PRNUSNEUROBO PHARMACEUTICALS APPOINTS HYUNG HEON KIM AS CHIEF..
09/8/202315:37EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/8/202315:20EDGAR2Form 8-K - Current report
09/8/202315:05PRNUSNeuroBo Pharmaceuticals Reports Second Quarter 2023..
08/8/202315:15EDGAR2Form 8-K - Current report
03/8/202307:15EDGAR2Form 8-K - Current report
03/8/202307:01PRNUSNeuroBo Pharmaceuticals Receives First Site IRB Approval for..
02/8/202307:01PRNUSNeuroBo Pharmaceuticals Enters Into Term Sheet With MThera..
28/7/202305:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/7/202305:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/7/202305:02EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
29/6/202307:36EDGAR2Form 8-K - Current report

Su Consulta Reciente

Delayed Upgrade Clock